Flipping the Switch
Buddy, ‘Gilenya’ Spare a Dime? Biogen Tops in Oral MS Space
By Randy Osborne
Tuesday, October 29, 2013
A surprise delay in the launch of Biogen Idec Inc.’s long-lasting recombinant factor VIII candidate for hemophilia A, Eloctate – partnered with Swedish Orphan Biovitrum (Sobi) – did little to dampen investor joy over third-quarter earnings, thanks to another home run with Tecfidera (dimethyl fumarate).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.